Replimune Group, Inc. — Investor Relations & Filings
Filings indexed
586
across all filing types
Latest filing
2026-02-20
Director's Dealing
Country
US
United States of America
Listing
US
REPL
Replimune Group, Inc. is a clinical-stage biotechnology company that develops oncolytic immunotherapies to treat cancer. The company's approach utilizes a proprietary platform to engineer viruses that are intended to selectively replicate within and destroy tumors while also activating a powerful, systemic, and durable anti-tumor immune response. Replimune's product candidates are being developed to treat a broad range of solid tumors, both as monotherapies and in combination with other cancer treatments. The company's mission is to revolutionize cancer treatment by inducing a comprehensive, tumor-specific immune activation.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 4 - REPLIMUNE GROUP, INC. (0001737953) (Filer) | 2026-02-20 | English | |
| SCHEDULE 13G/A Filing | 2026-02-17 | English | |
| 10-Q Filing | 2026-02-03 | English | |
| 8-K Filing | 2026-02-03 | English | |
| FORM 8-K | 2026-01-12 | English | |
| OWNERSHIP DOCUMENT | 2025-12-19 | English |
Browse filings by year
9 years| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
5 filings
| |||||
| 32897518 | 4 - REPLIMUNE GROUP, INC. (0001737953) (Filer) | 2026-02-20 | English | ||
| 31534227 | SCHEDULE 13G/A Filing | 2026-02-17 | English | ||
| 31534414 | 10-Q Filing | 2026-02-03 | English | ||
| 31534363 | 8-K Filing | 2026-02-03 | English | ||
| 13106220 | FORM 8-K | 2026-01-12 | English | ||
|
2025
10 filings
| |||||
| 13106221 | OWNERSHIP DOCUMENT | 2025-12-19 | English | ||
| 13106224 | OWNERSHIP DOCUMENT | 2025-12-19 | English | ||
| 13106223 | OWNERSHIP DOCUMENT | 2025-12-19 | English | ||
| 13106225 | OWNERSHIP DOCUMENT | 2025-12-19 | English | ||
| 13106222 | OWNERSHIP DOCUMENT | 2025-12-19 | English | ||
| 13106227 | OWNERSHIP DOCUMENT | 2025-12-11 | English | ||
| 13106228 | Regulatory Filings 2025 | 2025-12-09 | English | ||
| 13106229 | OWNERSHIP DOCUMENT | 2025-12-04 | English | ||
| 13106231 | Regulatory Filings 2025 | 2025-12-02 | English | ||
| 13106230 | OWNERSHIP DOCUMENT | 2025-11-19 | English | ||
Market data
Market data not available
Last price
Market cap
volume
Day range
today
52-week range
trailing
Price history
Peer group · Research and experimental development on natural sciences and engineering
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
Cardiol Therapeutics Inc.
Clinical-stage company developing anti-inflammatory therapi…
|
CRDL | CA | Professional, scientific and te… |
|
CASSAVA SCIENCES INC
Clinical-stage biotech developing treatments for Central Ne…
|
SAVA | US | Professional, scientific and te… |
|
Celcuity Inc.
Clinical-stage biotech developing targeted therapies for mu…
|
CELC | US | Professional, scientific and te… |
|
Cell Bio Human Tech Co., Ltd
Develops and manufactures cellulose-based nonwoven fabrics …
|
318160 | KR | Professional, scientific and te… |
|
CEL SCI CORP
Clinical-stage biotech developing immunotherapies for cance…
|
CVM | US | Professional, scientific and te… |
|
Celyad Oncology SA
Biotechnology company developing innovative CAR-T cell ther…
|
CYAD | BE | Professional, scientific and te… |
|
Ceres Power Holdings PLC
A developer of solid oxide technology for clean power and g…
|
CWR | GB | Professional, scientific and te… |
|
Certara, Inc.
Accelerates drug development using biosimulation software, …
|
CERT | US | Professional, scientific and te… |
|
CervoMed Inc.
A clinical-stage biotech developing treatments for age-rela…
|
CRVO | US | Professional, scientific and te… |
|
Chabiotech Co.,Ltd.
Develops cell/gene therapies and provides CDMO and bio-bank…
|
085660 | KR | Professional, scientific and te… |
Replimune Group, Inc. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/33193/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=33193 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=33193 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
Full reference: API reference · OpenAPI schema
cURL
$ curl https://api.financialreports.eu/api/filings/?company=33193 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 33193}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for Replimune Group, Inc. (id: 33193)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.
We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.